Semaglutide in the EU
EMA-approved as Ozempic since 2018, Wegovy since 2022, Rybelsus oral since 2020. Prescription rules vary by member state. Cross-border EEA Directive 2011/24 enables real price arbitrage. Wegovy supply was rationed across most of Europe through 2024; mostly recovered by Q1 2026, but specific member states (Germany, France) still see intermittent gaps.
EMA-approved Ozempic (T2D), Wegovy (chronic weight management), Rybelsus (oral T2D). Prescription-only. EEA Directive 2011/24 enables cross-border prescription validity.
What it actually costs.
Midpoint ranges, Eli Lilly brand unless noted. Updated April 2026.
Per month. Private GKV coverage rare. Wegovy supply tighter than Ozempic.
Per month. Varies by apotheek.
Per month. Farmacia network, lower end of EU range.
Per month. Assurance Maladie rarely covers weight indication. Saxenda still common as fallback.
Per month across EU. Cheaper than Wegovy injectable for needle-averse patients.
How to get it — on the right side of the line.
Local private prescription
Every EU member state has functioning online clinics or private GPs prescribing Wegovy + Ozempic. Pharmacies (apotheek, apotheke, farmacia) dispense.
Cross-border price arbitrage
Get prescribed in a lower-cost EU country (typically Spain, Portugal, Greece), dispense at home. Confirm your home pharmacy will accept the cross-border prescription before traveling.
What channels actually work here.
All EU member states. Wegovy supply recovering, Germany + France still intermittent.
Rare in EU — highly regulated.
Customs risk. Not recommended.
Fast-growing segment. Verify the prescriber is licensed in the EU country.
Wegovy demand has run ahead of supply across most of Europe since the 2024 shortage. Recovery has been uneven: Spain + Portugal + Netherlands now stable, Germany + France still see 1-3 week gaps in 2026. Cross-border arbitrage is real and legal under EEA Directive 2011/24 — Spain in particular has been the price-arbitrage anchor for German + Dutch + Nordic patients in 2025-26.
Tirzepatide in the EU
Mounjaro / Zepbound — dual GLP-1 + GIP agonist. Eli Lilly. Stronger weight effect head-to-head than semaglutide; also more expensive and supply has been more constrained globally.
Match me to a vendor in the EU.
Two minutes, five questions. Your match email has the vendor name, price, and the honest tradeoff.
We earn a small commission when you buy through recommended vendors. That is how this stays free. Vendors rank by quality signals, not paid placement.